BDKRB1 Antibody

What is BDKRB1 and why is it significant in research?

BDKRB1 (B1 Bradykinin Receptor) is a member of the seven-transmembrane domain, G protein-coupled receptor (GPCR) superfamily that responds to bradykinin-related peptides. Specifically, BDKRB1 is activated by des-Arg9-bradykinin and Lys-des-Arg9-bradykinin peptides. Originally considered to be non-expressed in healthy tissues, BDKRB1 expression is primarily inducible upon tissue injury and by inflammatory mediators such as bacterial lipopolysaccharide (LPS) and various cytokines. More recent research has demonstrated low-level expression of BDKRB1 in the central nervous system of rodents and primates. The receptor represents a significant therapeutic target for inflammatory disorders and cardiovascular diseases, making it an important focus in research .

How does BDKRB1 differ from BDKRB2 in terms of expression and function?

BDKRB1 and BDKRB2 are distinct bradykinin receptors with important functional differences. While BDKRB1 is generally inducible and upregulated during inflammatory conditions, BDKRB2 is constitutively expressed across various cell types. Both receptors belong to the GPCR superfamily and share structural similarities, including seven transmembrane domains, an extracellular amino terminus, and a cytoplasmic carboxyl terminus. Functionally, BDKRB1 responds to des-Arg9-bradykinin and Lys-des-Arg9-bradykinin, while BDKRB2 is activated by bradykinin (BK) and Lys-BK peptides. Both receptors can act through Giα to inhibit adenylate cyclase, offering multiple signaling pathways .

What primary applications are supported by BDKRB1 antibodies?

BDKRB1 antibodies support several key research applications:

• Western blot analysis - For detecting BDKRB1 protein expression in tissue and cellular lysates

• Immunohistochemistry - For localizing BDKRB1 in tissue sections, as demonstrated in rat brain, spinal cord, and other tissues

• Immunocytochemistry - For cellular localization studies in cultured cells

• ELISA - For quantitative protein detection

• Immunofluorescence - For visualizing receptor distribution

The selection of application should be guided by experimental objectives and the specific validation data available for each antibody.

What controls should be included when using BDKRB1 antibodies?

When designing experiments with BDKRB1 antibodies, appropriate controls are essential for validating specificity and ensuring reliable results:

• Negative controls:

  • Preincubation with specific blocking peptides (e.g., B1 Bradykinin Receptor/BDKRB1 Blocking Peptide) to confirm antibody specificity

  • Samples known not to express BDKRB1 (such as human peripheral blood lymphocytes)

  • Secondary antibody-only controls to assess non-specific binding

• Positive controls:

  • Tissues with documented BDKRB1 expression (e.g., rat brain sections, particularly amygdala, hippocampus, and cerebellum)

  • Cell lines with known BDKRB1 expression

  • Samples treated with inflammatory mediators known to upregulate BDKRB1 (e.g., IL-1β, serum, LPS)

These controls help distinguish specific signal from background and validate antibody specificity across experimental conditions.

How should dilution factors be optimized for different applications?

Optimal dilution factors vary by application technique and specific antibody. Based on available data:

Researchers should perform titration experiments to determine optimal antibody concentration for their specific sample type and detection system. Factors influencing optimal dilution include tissue fixation method, antigen retrieval techniques, and detection systems employed .

How can induction of BDKRB1 expression be achieved for experimental purposes?

For experimental induction of BDKRB1 expression, several approaches have been validated:

• Cytokine treatment: IL-1β treatment of human smooth muscle cells (SMCs) has been demonstrated to induce BDKRB1 expression

• Serum stimulation: Treatment with serum components can upregulate BDKRB1 in human SMCs

• LPS exposure: Concentration-dependent induction (1-50 ng/ml) of BDKRB1 mRNA and protein expression has been documented in human amnion fibroblasts

• SAA1 treatment: Serum amyloid A1 (10-100 ng/ml) induces BDKRB1 expression in a concentration-dependent manner

• TLR4-dependent mechanisms: Both LPS and SAA1-induced BDKRB1 expression can be blocked by TLR4 inhibitor CLI-095, indicating a role for this pathway

These induction protocols allow researchers to model inflammatory conditions and study BDKRB1 regulation in controlled experimental settings.

What are common issues when working with BDKRB1 antibodies and how can they be resolved?

Common technical challenges when working with BDKRB1 antibodies include:

• Low or undetectable signal:

  • Ensure target tissue actually expresses BDKRB1 (consider induction with inflammatory mediators)

  • Optimize antibody concentration through titration experiments

  • Employ more sensitive detection systems

  • Verify proper sample preparation and protein extraction methods

• Non-specific binding:

  • Perform blocking peptide experiments to confirm specificity

  • Increase blocking duration/concentration

  • Optimize washing steps

  • Consider alternative antibodies with validated specificity

• Species cross-reactivity limitations:

  • Confirm antibody specificity for your species of interest

  • Note that some antibodies (e.g., ABR-011) are designed to recognize rat/mouse BDKRB1 but may not detect human BDKRB1

  • Use antibodies specifically validated for human samples when working with human tissues

How can mRNA and protein expression of BDKRB1 be correlated effectively?

Correlating BDKRB1 mRNA and protein expression requires integrated approaches:

• Parallel analysis:

  • Extract RNA and protein from the same samples

  • Perform qRT-PCR for mRNA quantification

  • Use western blot or ELISA for protein detection

  • Compare expression patterns across similar timepoints

• Methodological considerations:

  • For RNA analysis: Use DNase I treatment of RNA samples to prevent genomic DNA contamination

  • For RT-PCR: Employ duplex RT-PCR with appropriate housekeeping genes

  • For protein detection: Select antibodies with demonstrated specificity

  • Consider post-transcriptional regulation that may affect correlation

• Time-course experiments:

  • Account for temporal delay between mRNA induction and protein expression

  • Sample at multiple timepoints following stimulation with inflammatory mediators

Research has demonstrated that both mRNA and protein levels of BDKRB1 increase following stimulation with inflammatory mediators like SAA1 and LPS, providing complementary evidence of receptor upregulation.

What are important storage and handling considerations for BDKRB1 antibodies?

Proper storage and handling of BDKRB1 antibodies are crucial for maintaining activity and specificity:

• Long-term storage:

  • Store at -20°C for up to one year

  • Aliquot antibodies upon receipt to minimize freeze-thaw cycles

• Short-term storage:

  • For frequent use, store at 4°C for up to one month

• Avoid repeated freeze-thaw cycles:

  • Each cycle can degrade antibody quality and reduce performance

• Buffer composition:

  • Most commercially available BDKRB1 antibodies are provided in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

  • This formulation enhances stability and prevents microbial contamination

• Working dilutions:

  • Prepare fresh working dilutions on the day of use

  • Return stock solutions to appropriate storage conditions immediately after use

How can BDKRB1 antibodies be utilized to study receptor regulation at the promoter level?

Advanced studies of BDKRB1 gene regulation can employ antibodies in conjunction with other molecular techniques:

• Chromatin immunoprecipitation (ChIP) assays:

  • Use antibodies against transcription factors identified through footprinting analyses

  • Target factors binding to the -1349/+42 core promoter region of BDKRB1

  • Correlate ChIP data with in vivo footprinting results

• Integration with footprinting analysis:

  • In vivo DNase I-mediated footprinting has been used to identify protein-DNA interactions in the BDKRB1 promoter

  • Ligation-mediated PCR (LMPCR) with specific primers can map functional domains of the BDKRB1 promoter

  • Compare footprinting patterns between cells expressing and not expressing functional BDKRB1

• Correlation studies:

  • Analyze how transcription factor binding correlates with BDKRB1 protein expression

  • Use BDKRB1 antibodies to confirm protein expression following transcriptional activation

  • Link promoter activity to functional receptor expression

These approaches enable mechanistic studies of how inflammation-induced transcription factors regulate BDKRB1 expression.

What methodologies can evaluate BDKRB1 expression in neuroinflammatory models?

BDKRB1 antibodies are valuable tools for studying neuroinflammation:

• Immunohistochemical mapping:

  • BDKRB1 antibodies have been used to detect expression in neuronal cells of the amygdala, hippocampus (CA1), and Purkinje cell axons in cerebellum

  • These studies reveal previously underappreciated constitutive expression in specific brain regions

• Primary neuronal culture studies:

  • Antibodies have been applied to rat trigeminal neuron primary cultures

  • Immunocytochemical staining of trigeminal ganglion (TG) neurons allows cellular localization studies

• Functional correlations:

  • Combine receptor localization with functional assays

  • Compare receptor expression with calcium signaling or other second messengers

  • Correlate with behavioral or electrophysiological outcomes in animal models

• Neuroinflammatory models:

  • Apply antibodies to tissues from models of neuropathic pain, stroke, or neurodegenerative conditions

  • Monitor changes in receptor expression and distribution following inflammatory challenge

This multi-modal approach enables comprehensive understanding of BDKRB1's role in neuroinflammatory processes.

How can BDKRB1 antibodies contribute to understanding receptor signaling mechanisms?

Understanding the complex signaling pathways downstream of BDKRB1 activation requires sophisticated experimental approaches:

• Co-immunoprecipitation studies:

  • Use BDKRB1 antibodies to pull down receptor complexes

  • Identify associated G-proteins and signaling molecules

  • Detect changes in protein interactions following receptor activation

• Signaling pathway analysis:

  • BDKRB1 and BDKRB2 can act through Giα to inhibit adenylate cyclase

  • Investigate phosphorylation events downstream of receptor activation

  • Combine with pharmacological inhibitors to dissect pathway components

• Receptor trafficking studies:

  • Monitor receptor internalization and recycling using immunofluorescence

  • Track changes in receptor localization following ligand binding

  • Assess the impact of inflammatory conditions on trafficking dynamics

• Functional readouts:

  • Correlate receptor expression detected by antibodies with functional outcomes

  • In amnion fibroblasts, pretreatment with inflammatory mediators (SAA1, LPS) followed by BDKRB1 ligand (DABK) treatment induces PTGS2 expression

  • This provides a model system for studying how receptor upregulation impacts downstream signaling

How should contradictory results between different detection methods for BDKRB1 be reconciled?

When facing contradictory results between different detection methods:

• Validate antibody specificity for each technique:

  • Western blot may detect denatured epitopes not accessible in immunohistochemistry

  • Use blocking peptides specific to each technique to confirm specificity

  • Consider multiple antibodies targeting different epitopes

• Address technical factors:

  • Fixation methods can affect epitope availability in IHC/ICC

  • Sample preparation may impact protein conformation

  • Detection system sensitivity varies across techniques

• Correlate with functional data:

  • Complement protein/RNA detection with functional assays

  • Use receptor agonists/antagonists to confirm functional expression

  • Consider reporter systems to monitor receptor activation

• Consider biological factors:

  • Post-translational modifications may affect antibody recognition

  • Receptor expression levels vary across tissues and conditions

  • Inducible nature of BDKRB1 means timing of analysis is critical

A comprehensive approach using multiple techniques provides the most reliable characterization of BDKRB1 expression.

What are the important considerations when comparing BDKRB1 expression across different species?

Cross-species comparisons of BDKRB1 expression require careful consideration:

• Antibody selection:

  • Confirm antibody cross-reactivity with target species

  • Some antibodies (e.g., ABR-011) recognize rat and mouse BDKRB1 but not human

  • Others (e.g., A05724-1) are specifically designed for human BDKRB1 detection

• Sequence homology analysis:

  • Review sequence conservation at antibody epitope sites

  • The ABR-011 antibody targets amino acid residues 243-257 of rat B1R with a specific modification (replacement of cysteine 250 with serine)

  • Human BDKRB1 antibodies may target different regions (e.g., A05724-1 targets AA range 201-250)

• Expression pattern differences:

  • BDKRB1 was originally considered absent in healthy tissues, but recent work shows low-level expression in rodent and primate CNS

  • Species differences in constitutive expression should be considered

  • Induction patterns may vary between species

• Experimental validation:

  • Include positive controls from each species

  • Consider species-specific positive control tissues

These considerations ensure accurate cross-species comparisons and prevent misinterpretation of species-specific differences.